Intuitive Surgical, Inc. $ISRG Shares Sold by Wealth Enhancement Trust Services Inc.

Posted by on Oct 7th, 2026

Wealth Enhancement Trust Services Inc. reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) by 13.5% during the 3rd quarter, Holdings Channel reports. The firm owned 8,458 shares of the medical equipment provider’s stock after selling 1,323 shares during the quarter. Wealth Enhancement Trust Services Inc.’s holdings in Intuitive Surgical were worth $3,439,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ISRG. Motiv8 Investments LLC acquired a new stake in Intuitive Surgical in the 4th quarter valued at $34,000. Main Street Group LTD acquired a new position in Intuitive Surgical during the first quarter worth $30,000. North Point Portfolio Managers Corp OH acquired a new position in Intuitive Surgical during the third quarter worth $27,000. Vermillion Wealth Management Inc. lifted its holdings in Intuitive Surgical by 58.1% during the first quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 25 shares in the last quarter. Finally, Evergreen Advisors LLC acquired a new stake in shares of Intuitive Surgical in the first quarter valued at about $35,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

  • Positive Sentiment: Barclays began coverage of Intuitive Surgical with an Overweight rating, adding a new bullish view on the shares. Barclays starts coverage of Intuitive Surgical stock at Overweight
  • Positive Sentiment: Citi reportedly assigned ISRG a Buy rating, reinforcing the recent improvement in sell-side sentiment. Intuitive Surgical gets a Buy from Citi
  • Positive Sentiment: Intuitive Surgical’s single-port robotic platform is gaining traction, with rising procedures, utilization and system placements. Expanding clinical indications and international adoption could turn the platform into a major billion-dollar franchise and provide an additional growth engine beyond the company’s established da Vinci systems. Can ISRG’s Single-Port Platform Become the Next Billion-Dollar Franchise?
  • Positive Sentiment: Recent commentary argues that the stock’s valuation multiple has fallen while the underlying growth story remains intact. A recovery in system sales, procedure volumes and recurring instruments-and-accessories revenue could support a rebound after a weak trailing year. Intuitive Surgical: The Multiple Fell, The Story Didn’t
  • Neutral Sentiment: An industry outlook highlighted Intuitive Surgical alongside Globus Medical and Thermo Fisher Scientific, but provided limited company-specific detail or a clear new catalyst. Zacks Industry Outlook
  • Negative Sentiment: Jim Cramer expressed less enthusiasm for ISRG, citing the growing number of competitors—particularly Johnson & Johnson—as a threat to the company’s long-term positioning. This underscores the risk that competition could pressure growth or valuation. Intuitive Surgical and JNJ Give Jim Cramer More Than Valuation to Consider

Insider Buying and Selling

In other news, VP Fredrik Widman sold 1,089 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $374.44, for a total value of $407,765.16. Following the completion of the sale, the vice president owned 1,026 shares of the company’s stock, valued at $384,175.44. This represents a 51.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89. Following the sale, the executive vice president owned 881 shares of the company’s stock, valued at $330,877.17. This represents a 8.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock worth $4,891,989 over the last ninety days. 0.60% of the stock is currently owned by insiders.

Intuitive Surgical Stock Up 2.4%

Shares of ISRG traded up $9.76 during midday trading on Wednesday, reaching $414.52. The company had a trading volume of 1,895,998 shares, compared to its average volume of 2,423,132. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88. The firm has a 50 day simple moving average of $383.70 and a 200-day simple moving average of $411.61. The stock has a market cap of $146.44 billion, a PE ratio of 47.48, a price-to-earnings-growth ratio of 3.07 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm had revenue of $2.89 billion during the quarter, compared to analyst estimates of $2.83 billion. During the same quarter in the prior year, the firm posted $1.81 earnings per share. Intuitive Surgical’s quarterly revenue was up 18.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. BTIG Research restated a “buy” rating and set a $469.00 price target on shares of Intuitive Surgical in a research report on Tuesday, September 8th. Leerink Partners decreased their target price on Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating on the stock in a research report on Friday, July 17th. BNP Paribas Exane raised Intuitive Surgical to an “outperform” rating in a research note on Tuesday, July 28th. Mizuho set a $500.00 price objective on Intuitive Surgical and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, Robert W. Baird dropped their target price on shares of Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating for the company in a report on Friday, July 17th. Twenty-two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $502.53.

Read Our Latest Research Report on ISRG

Intuitive Surgical Company Profile

(Free Report)

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.

Featured Stories

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report).

Institutional Ownership by Quarter for Intuitive Surgical (NASDAQ:ISRG)

Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.